FDA Authorizes At-Home Initial Dosing for Alzheimer's Drug Lecanemab

The U.S. Food and Drug Administration has approved an at-home starting dose for lecanemab, an Alzheimer's treatment. This decision aims to broaden access for patients with early-stage Alzheimer's disease who have confirmed elevated beta-amyloid levels. This expands on previous approvals for the drug and its maintenance dosing, potentially making treatment more accessible.